NASDAQ:ACORAcorda Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Acorda Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.76 +0.01 (+1.34 %) (As of 05/22/2020 04:00 PM ET) Add Compare Share Today's Range$0.72Now: $0.76▼$0.7650-Day Range$0.74MA: $0.93▼$1.2052-Week Range$0.70Now: $0.76▼$10.97Volume1.63 million shsAverage Volume2.45 million shsMarket Capitalization$36.26 millionP/E RatioN/ADividend YieldN/ABeta1.62 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease; an inhaled triptan (zolmitriptan) for acute treatment of migraine by using the ARCUS drug delivery technology; SYN120, which is completed Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) for primary sclerosing cholangitis. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.Read More Beat the Market (BTM) Rank™ 3.0 Analyst's Opinion Consensus RatingAcorda Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 4 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.07, Acorda Therapeutics has a potential upside of 835.2% from its current price of $0.76.Amount of Analyst CoverageAcorda Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.2 Community Rank Outperform VotesAcorda Therapeutics has received 423 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAcorda Therapeutics has received 535 “underperform” votes. (Add your “underperform” vote.)Community SentimentAcorda Therapeutics has received 55.85% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Acorda Therapeutics and other stocks. Vote “Outperform” if you believe ACOR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ACOR will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAcorda Therapeutics does not currently pay a dividend.Dividend GrowthAcorda Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acorda Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.10% of the stock of Acorda Therapeutics is held by insiders. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Acorda Therapeutics are expected to grow in the coming year, from ($1.96) to ($1.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acorda Therapeutics is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acorda Therapeutics is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcorda Therapeutics has a P/B Ratio of 0.12. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.29 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:ACOR Previous Symbol CUSIP00484M10 CIK1008848 Webwww.acorda.com Phone914-347-4300Debt Debt-to-Equity Ratio0.79 Current Ratio2.38 Quick Ratio2.02Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$192.41 million Price / Sales0.19 Cash Flow$4.72 per share Price / Cash Flow0.16 Book Value$6.39 per share Price / Book0.12Profitability EPS (Most Recent Fiscal Year)($1.99) Net Income$-272,970,000.00 Net Margins-131.45% Return on Equity-19.83% Return on Assets-7.88%Miscellaneous Employees474 Outstanding Shares47,990,000Market Cap$36.26 million Next Earnings Date8/6/2020 (Estimated) OptionableOptionable NASDAQ:ACOR Rates by TradingView Receive ACOR News and Ratings via Email Sign-up to receive the latest news and ratings for ACOR and its competitors with MarketBeat's FREE daily newsletter. Acorda Therapeutics (NASDAQ:ACOR) Frequently Asked Questions How has Acorda Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Acorda Therapeutics' stock was trading at $1.01 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ACOR shares have decreased by 25.2% and is now trading at $0.7556. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Acorda Therapeutics? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acorda Therapeutics in the last year. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Acorda Therapeutics. When is Acorda Therapeutics' next earnings date? Acorda Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Acorda Therapeutics. How were Acorda Therapeutics' earnings last quarter? Acorda Therapeutics Inc (NASDAQ:ACOR) released its quarterly earnings results on Tuesday, May, 5th. The biopharmaceutical company reported ($0.51) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.56) by $0.05. The biopharmaceutical company earned $28.10 million during the quarter, compared to the consensus estimate of $39.34 million. Acorda Therapeutics had a negative net margin of 131.45% and a negative return on equity of 19.83%. View Acorda Therapeutics' earnings history. What price target have analysts set for ACOR? 6 Wall Street analysts have issued twelve-month price objectives for Acorda Therapeutics' shares. Their forecasts range from $1.40 to $12.00. On average, they expect Acorda Therapeutics' share price to reach $7.07 in the next twelve months. This suggests a possible upside of 835.2% from the stock's current price. View analysts' price targets for Acorda Therapeutics. What are Wall Street analysts saying about Acorda Therapeutics stock? Here are some recent quotes from research analysts about Acorda Therapeutics stock: 1. Stifel Nicolaus analysts commented, "Stifel analyst Paul Matteis lowered the price target on Acorda Therapeutics, Inc. (NASDAQ: ACOR) to $7.00 (from $12.00) while maintaining a Hold rating." (8/2/2019) 2. According to Zacks Investment Research, "Acorda got a huge boost with the approval of Inbrija in the United States, slightly before the scheduled time period. The drug is also under review in the EU with a decision expected in 2019. Inbrija was launched in February and registered its first sales in the first quarter. Acorda is seeking collaborations on the ex-U.S. commercialization of Inbrija with potential partners both across Europe and Japan. However, its key multiple sclerosis drug Ampyra is facing a generic competition which is significantly hurting Acorda’s top-line. The company expects to see a persistent decline in Ampyra sales during the quarters ahead in 2019. Shares of Acorda have underperformed the industry in the year so far. Nonetheless, Acorda boasts a strong pipeline addressing a wide range of disorders. The restructuring initiative is also saving costs." (7/3/2019) Has Acorda Therapeutics been receiving favorable news coverage? News coverage about ACOR stock has been trending positive on Sunday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Acorda Therapeutics earned a daily sentiment score of 2.1 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutAcorda Therapeutics. Are investors shorting Acorda Therapeutics? Acorda Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 14,190,000 shares, an increase of 8.4% from the April 30th total of 13,090,000 shares. Based on an average trading volume of 1,640,000 shares, the days-to-cover ratio is presently 8.7 days. Approximately 30.1% of the shares of the stock are short sold. View Acorda Therapeutics' Current Options Chain. Who are some of Acorda Therapeutics' key competitors? Some companies that are related to Acorda Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Ionis Pharmaceuticals (IONS). View all competitors. What other stocks do shareholders of Acorda Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Acorda Therapeutics investors own include InterDigital Wireless (IDCC), Nektar Therapeutics (NKTR), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Applied Materials (AMAT), Intel (INTC), Novavax (NVAX), Western Digital (WDC), salesforce.com (CRM) and FTS International (FTSI). Who are Acorda Therapeutics' key executives? Acorda Therapeutics' management team includes the following people: Dr. Ron Cohen, Founder, CEO, Pres & Director (Age 63)Mr. David Lawrence, Chief Technology officer, Chief of Bus. Operations & Principal Accounting Officer (Age 61)Ms. Lauren M. Sabella, Chief Commercial Officer (Age 58)Mr. Andrew Asa Hindman, Chief Bus. Officer (Age 46)Dr. Burkhard Blank, Chief Medical Officer and Head of R&D (Age 64) What is Acorda Therapeutics' stock symbol? Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR." Who are Acorda Therapeutics' major shareholders? Acorda Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (15.26%), Acadian Asset Management LLC (3.95%), State Street Corp (3.11%), Invesco Ltd. (2.05%), AQR Capital Management LLC (1.84%) and Geode Capital Management LLC (1.35%). Company insiders that own Acorda Therapeutics stock include Andrew A Hindman, Burkhard Blank, David Lawrence, Ian F Smith, Jane Wasman, Lauren M Sabella, Lorin Randall, Ron Cohen and Scopia Capital Management Lp. View institutional ownership trends for Acorda Therapeutics. Which institutional investors are selling Acorda Therapeutics stock? ACOR stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., AQR Capital Management LLC, Russell Investments Group Ltd., Parametric Portfolio Associates LLC, Two Sigma Investments LP, Connor Clark & Lunn Investment Management Ltd., Geode Capital Management LLC, and Principal Financial Group Inc.. Company insiders that have sold Acorda Therapeutics company stock in the last year include Jane Wasman, and Ron Cohen. View insider buying and selling activity for Acorda Therapeutics. Which institutional investors are buying Acorda Therapeutics stock? ACOR stock was acquired by a variety of institutional investors in the last quarter, including Invesco Ltd., JPMorgan Chase & Co., GSA Capital Partners LLP, Strs Ohio, Federated Hermes Inc., Massachusetts Financial Services Co. MA, Salzhauer Michael, and Acadian Asset Management LLC. View insider buying and selling activity for Acorda Therapeutics. How do I buy shares of Acorda Therapeutics? Shares of ACOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Acorda Therapeutics' stock price today? One share of ACOR stock can currently be purchased for approximately $0.76. How big of a company is Acorda Therapeutics? Acorda Therapeutics has a market capitalization of $36.26 million and generates $192.41 million in revenue each year. The biopharmaceutical company earns $-272,970,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Acorda Therapeutics employs 474 workers across the globe. What is Acorda Therapeutics' official website? The official website for Acorda Therapeutics is www.acorda.com. How can I contact Acorda Therapeutics? Acorda Therapeutics' mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The biopharmaceutical company can be reached via phone at 914-347-4300. This page was last updated on 5/24/2020 by MarketBeat.com Staff
